Isotypes of autoantibodies against novel differential 4-hydroxy-2-nonenal-modified peptide adducts in serum is associated with rheumatoid arthritis in Taiwanese women

Tsai, Kai-Leun; Chang, Che-Chang; Chang, Yu-Sheng; Lu, Yi-Ying; Tsai, I-Jung; Chen, Jin-Hua; Lin, Sheng-Hong; Tai, Chih-Chun; Lin, Yi-Fang; Chang, Hui-Wen; Lin, Ching-Yu; Su, Emily Chia-Yu

doi:10.1186/s12911-020-01380-y

BMC Medical Informatics and Decision Making

Table 4 Associations of 4-hydroxy-2-nonenal (HNE)-protein adducts and autoantibody isotypes against unmodified and HNE-modified peptides in rheumatoid arthritis (RA) patients vs. healthy controls (HCs)

From: Isotypes of autoantibodies against novel differential 4-hydroxy-2-nonenal-modified peptide adducts in serum is associated with rheumatoid arthritis in Taiwanese women

Risk factor		Cutoff	HC	RA	Age-adjusted logistic regression model^a	p value	Power
Risk factor		Cutoff	(n)	(n)	OR (95% CI)	p value	Power
HNE-protein adduct	<	2.386	26	24	1.0 (Ref)	0.014	0.743
HNE-protein adduct	≥	2.386	34	71	2.413 (1.193, 4.880)
IgG anti-CFAH^1121−1230	<	0.175	14	8	1.0 (Ref)	0.013	0.874
IgG anti-CFAH^1121−1230	≥	0.175	46	87	3.293 (1.286, 8.431)
IgG anti-CFAH^1121−1230 HNE	<	0.263	46	51	1.0 (Ref)	0.005	0.870
IgG anti-CFAH^1121−1230 HNE	≥	0.263	14	44	2.808 (1.363, 5.785)
IgM anti-CFAH^1121−1230	<	0.609	35	20	1.0 (Ref)	< 0.001	0.979
IgM anti-CFAH^1121−1230	≥	0.609	25	75	5.204 (2.550, 10.617)
IgM anti-CFAH^1121−1230 HNE	<	0.333	39	39	1.0 (Ref)	0.004	0.838
IgM anti-CFAH^1121−1230 HNE	≥	0.333	21	56	2.700 (1.378, 5.289)
IgG anti-HPT⁷⁸⁻¹⁰⁸	<	0.662	35	37	1.0 (Ref)	0.024	0.645
IgG anti-HPT⁷⁸⁻¹⁰⁸	≥	0.662	25	58	2.156 (1.108, 4.193)
IgG anti-HPT⁷⁸⁻¹⁰⁸ HNE	<	0.307	41	51	1.0 (Ref)	0.094	0.455
IgG anti-HPT⁷⁸⁻¹⁰⁸ HNE	≥	0.307	19	44	1.821 (0.904, 3.672)
IgM anti-HPT⁷⁸⁻¹⁰⁸	<	0.326	40	42	1.0 (Ref)	0.005	0.841
IgM anti-HPT⁷⁸⁻¹⁰⁸	≥	0.326	20	53	2.695 (1.356, 5.354)
IgM anti-HPT⁷⁸⁻¹⁰⁸ HNE	<	0.187	39	25	1.0 (Ref)	< 0.001	0.985
IgM anti-HPT⁷⁸⁻¹⁰⁸ HNE	≥	0.187	21	70	5.235 (2.594, 10.565)
IgG anti-IGKC²⁻¹⁹	<	0.392	35	22	1.0 (Ref)	< 0.001	0.974
IgG anti-IGKC²⁻¹⁹	≥	0.392	25	73	4.679 (2.317, 9.449)
IgG anti-IGKC²⁻¹⁹ HNE	<	0.427	33	26	1.0 (Ref)	< 0.001	0.905
IgG anti-IGKC²⁻¹⁹ HNE	≥	0.427	27	69	3.206 (1.621, 6.340)
IgM anti-IGKC²⁻¹⁹	<	0.743	56	50	1.0 (Ref)	< 0.001	> 0.999
IgM anti-IGKC²⁻¹⁹	≥	0.743	4	45	12.655 (4.244, 37.734)
IgM anti-IGKC²⁻¹⁹ HNE	<	0.738	53	47	1.0 (Ref)	< 0.001	> 0.999
IgM anti-IGKC²⁻¹⁹ HNE	≥	0.738	7	48	8.095 (3.312, 19.780)
IgG anti-THRB^328−345	<	0.154	19	7	1.0 (Ref)	< 0.001	0.951
IgG anti-THRB^328−345	≥	0.154	41	88	5.761 (2.228, 14.895)
IgG anti-THRB^328−345 HNE	<	0.281	26	7	1.0 (Ref)	< 0.001	0.962
IgG anti-THRB^328−345 HNE	≥	0.281	34	88	9.524 (3.777, 24.012)
IgM anti-THRB^328−345	<	0.791	46	56	1.0 (Ref)	0.029	0.697
IgM anti-THRB^328−345	≥	0.791	14	39	2.249 (1.086, 4.659)
IgM anti-THRB^328−345 HNE	<	0.682	48	42	1.0 (Ref)	< 0.001	0.992
IgM anti-THRB^328−345 HNE	≥	0.682	12	53	5.043 (2.377, 10.696)

^aOR, odds ratio; Ref, reference value

Back to article page

ISSN: 1472-6947

Contact us

General enquiries: journalsubmissions@springernature.com